Specialties

Internal Medicine, Mycobacterial Diseases, Public Health and Infectious Disease Epidemiology

Education

B.A. - Yale University
M.D. - Oregon Health & Science University
M.P.H. (Epidemiology) - University of California at Berkeley

Professional training

Residency (Ophthalmology) - Stanford University
Epidemic Intelligence Service Officer - US Public Health Service, US Centers for Diseases Control and Prevention
Residency (Internal Medicine) - Legacy Emanuel Hospital, Portland, Oregon
Fellowship (Mycobacterial Diseases) - National Jewish Medical Center, Denver, Colorado

Clinical interests

• Chronic chest infections of all etiology, including mycobacteria
• The prevention and treatment of infections associated with Biologics and other Immunosuppressive therapies
• Tuberculosis of the eye (Ophthalmology)

Research interests

• Onchocerchiasis (river blindness) treatment and diagnosis
• Prevention and treatment of opportunistic infections in patients receiving novel immunosuppressive therapies
• Epidemiology of tuberculosis and non-TB mycobacterial infections
• International ophthalmology education and training
• Therapeutic development and clinical trials related to bronchiectasis, NTM, and other chronic chest infections
• Epidemiology and prevention of herpes zoster

Brief bio

Kevin Winthrop, M.D., M.P.H. – is principal investigator and Director of the Center for Infectious Disease Studies. Dr. Winthrop is a Professor of Public Health at the School of Public Health and a Professor of Infectious Diseases and Ophthalmology at the School of Medicine at OHSU. He is a former infectious disease epidemiologist with the Division of Tuberculosis Elimination at the U.S. Centers for Disease Control and Prevention.

Representative publications

1. Winthrop KL, Weinblatt ME, Crow MK, Burmester GR…Furst DE. (2019). Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018. Annals of the Rheumatic Diseases. doi: 10.1136/annrheumdis-2018-214280. [Epub ahead of print]
2. Henkle E, Curtis JR, Chen L, Chan B, Aksamit TR, Daley CL, Griffith DE, Winthrop KL. (2019 Apr 18). Comparative Risks of Chronic Inhaled Corticosteroids and Macrolides for Bronchiectasis. European Respiratory Journal. doi: 10.1183/13993003.01896-2018. [Epub ahead of print].
3. Winthrop, K, Saag, K, Cascino M, Pei J, John A, Jahreis A, Haselkorn T, Furst D. (2018 Oct 2) Long-Term Safety of Rituximab in Rheumatoid Arthritis: Analysis From the SUNSTONE Registry. Arthritis Care Res. doi: 10.1002/acr.23781 [Epub ahead of print].
4. Winthrop KL, Melmed GY, Vermeire S, Long MD, Chan G, Pedersen RD, Lawendy N, Thorpe AJ, Nduaka CI, Su C. Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib. Inflamm Bowel Dis. 2018 Sept 15:24(10)2258-2265. doi: 10.1093/ibd/izy131.
5. Birch DG, Bernstein PS, Iannacone A, Pennesi ME, Lam BL, Heckenlively J, Csaky K, Hartnett ME, Winthrop KL, Jayasundera T, Hughbanks-Wheaton DK, Warner J, Yang P, Fish GE, Teske MP, Sklaver NL, Erker L, Chegarnov E, Smith T, Wahle A, VanVeldhuisen PC, McCormack J, Lindblad R, Bramer S, Rose S, Zilliox P, Francis PJ, Weleber RG. Effect of Oral Valproic Acid vs Placebo for Vision Loss in Patients With Autosomal Dominant Retinitis Pigmentosa: A Randomized Phase 2 Multicenter Placebo-Controlled Clinical Trial. JAMA Ophthalmol. 2018 Aug 1;136(8):849-856. doi: 10.1001/jamaophthalmol.2018.1171.
6. Henkle E, Aksamit TR, Daley CL, Griffith DE, O'Donnell AE, Quittner AL, Malanga E, Prieto D, Leitman A, Winthrop KL. U.S. patient-centered research priorities and roadmap for bronchiectasis. Chest. doi: 10.1016/j.chest.2018.06.032. Epub 2018 Jul 5.
7. Jones MM, Winthrop KL, Nelson SD, Duvall SL, Patterson OV, Nechodom KE, Findley KE, Radonovich LJ Jr, Samore MH, Fennelly KP. Epidemiology of nontuberculous mycobacterial infections in the U.S. Veterans Health Administration. PLoS One. 2018 Jun 13;13(6):e0197976. doi: 10.1371/journal.pone.0197976. eCollection 2018.
8. Horne DJ, Jones BE, Kamada A, Fukushima K, Winthrop KL, Siegel SAR, Kovacs A, Anthony P, Meekin KA, Bhat S, Kerndt P, Chang A, Koelle DM, Narita M. Multicenter study of QuantiFERON^®-TB Gold Plus in patients with active tuberculosis. Int J Tuberc Lung Dis. 2018 Jun 1;22(6):617-621. doi: 10.5588/ijtld.17.0721.
9. Park JK, Lee YJ, Shin K, Ha YJ, Lee EY, Song YW, Choi Y, Winthrop KL, Lee EB. Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis. 2018 Jun;77(6):898-904. doi: 10.1136/annrheumdis-2018-213222. Epub 2018 Mar 23.
10. Winthrop KL, Korman N, Abramovits W, Rottinghaus ST, Tan H, Gardner A, Mukwaya G, Kaur M, Valdez H. T-cell-mediated immune response to pneumococcal conjugate vaccine (PCV-13) and tetanus toxoid vaccine in patients with moderate-to-severe psoriasis during tofacitinib treatment. J Am Acad Dermatol. 2018 Jun;78(6):1149-1155.  doi: 10.1016/j.jaad.2017.09.076. Epub 2018 Mar 2.
11. Winthrop KL, Baddley JW. Pneumocystis and glucocorticoid use: to prophylax or not to prophylax (and when?); that is the question. Ann Rheum Dis. 2018 May;77(5):631-633. doi: 10.1136/annrheumdis-2017-212588. Epub 2018 Feb 19.
12. Van Ingen J, Aksamit T, Andrejak C, Böttger EC, Cambau E, Daley CL, Griffith DE, Guglielmetti L, Holland SM, Huitt GA, Koh WJ, Lange C, Leitman P, Marras TK, Morimoto K, Olivier KN, Santin M, Stout JE, Thomson R, Tortoli E, Wallace RJ Jr, Winthrop KL, Wagner D; for NTM-NET. Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement. Eur Respir J. 2018 Mar 22;51(3). pii: 1800170. doi: 10.1183/13993003.00170-2018. Print 2018 Mar.
13. Metersky ML, Aksamit TR, Barker A, Choate R, Daley CL, Daniels LA, DiMango A, Eden E, Griffith D, Johnson M, Knowles M, O'Donnell AE, Olivier K, Salathe M, Thomashow B, Tino G, Turino G, Winthrop KL, Mannino D. The Prevalence and Significance of Staphylococcus aureus in Patients with Non-Cystic Fibrosis Bronchiectasis. Ann Am Thorac Soc. 2018 Mar;15(3):365-370. doi: 10.1513/AnnalsATS.201706-426OC.
14. McDonagh MS, Peterson K, Winthrop K, Cantor A, Lazur BH, Buckley DI. Interventions to reduce inappropriate prescribing of antibiotics for acute respiratory tract infections: summary and update of a systematic review. J Int Med Res. 2018 Aug;46(8):3337-3357. doi: 10.1177/0300060518782519. Epub 2018 Jul 1.
15. Aksamit T, De Soyza A, Bandel TJ, Criollo M, Elborn JS, Operschall E, Polverino E, Roth K, Winthrop KL, Wilson R. RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis. Eur Respir J. 2018 Jan 25;51(1). pii: 1702053. doi: 10.1183/13993003.02053-2017. Print 2018 Jan.
16. De Soyza A, Aksamit T, Bandel TJ, Criollo M, Elborn JS, Operschall E, Polverino E, Roth K, Winthrop KL, Wilson R. RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis. Eur Respir J. 2018 Jan 25;51(1). pii: 1702052. doi: 10.1183/13993003.02052-2017. Print 2018 Jan.
17. Winthrop KL, Strand V, van der Heijde D, Mease P, Crow M, Weinblatt M, Bathon J, Burmester GR, Dougados M, Kay J, Mariette X, Van Vollenhoven R, Sieper J, Melchers F, Breedfeld FC, Kalden J, Smolen JS, Furst DE. The unmet need in rheumatology: Reports from the targeted therapies meeting 2017. Clin Immunol. 2018 Jan;186:87-93. doi: 10.1016/j.clim.2017.08.009. Epub 2017 Aug 12.
18. Curtis JR, Winthrop K, O'Brien C, Ndlovu MN, de Longueville M, Haraoui B. Use of a baseline risk score to identify the risk of serious infectious events in patients with rheumatoid arthritis during certolizumab pegol treatment. Arthritis Res Ther. 2017 Dec 15;19(1):276. doi: 10.1186/s13075-017-1466-y.
19. Henkle E, Aksamit TR, Barker AF, Curtis JR, Daley CL, Anne Daniels ML, DiMango A, Eden E, Fennelly K, Griffith DE, Johnson M, Knowles MR, Leitman A, Leitman P, Malanga E, Metersky ML, Noone PG, O'Donnell AE, Olivier KN, Prieto D, Salathe M, Thomashow B, Tino G, Turino G, Wisclenny S, Winthrop KL. Pharmacotherapy for Non-Cystic Fibrosis Bronchiectasis: Results From an NTM Info & Research Patient Survey and the Bronchiectasis and NTM Research Registry. Chest. 2017 Dec;152(6):1120-1127. doi: 10.1016/j.chest.2017.04.167. Epub 2017 May 5

Back to ID Faculty Listing